Navigation Links
Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
Date:8/14/2012

ed to 36 percent of the zoledronic acid patients.

Denosumab also delayed the time to bone radiation by 26 percent compared to zoledronic acid.

And when asked about their quality of life, 10 percent more of those on denosumab had a "meaningful" improvement in quality of life compared to those on zoledronic acid.

The U.S. Food and Drug Administration approved Xgeva, made by California-based Amgen, for preventing bone complications caused by cancer in late 2010. Amgen funded the study. Stopeck, who is also director of the clinical breast cancer program at the University of Arizona's cancer center, has been a consultant and advisor for both Amgen and Novartis, which makes Zometa.

While the researchers say the study provides additional evidence that denosumab outperforms zoledronic acid in this group of patients, Dr. Joanne Mortimer, director of the women's cancer program at the City of Hope Comprehensive Cancer Center in Duarte, Calif., said it is too soon to say one will replace the other.

The downside of zoledronic acid is that patients' kidney function must be monitored and perhaps adjusted before each dose. That's not needed with denosumab.

However, zoledronic acid may have an anti-tumor effect, and it remains in the body longer than denosumab, she said. "And we don't have long-term results from denosumab," Mortimer added.

Cost is another consideration. While denosumab is about $1,650 an injection (plus fees for administering), zoledronic acid costs about $900 to $1,000. Also, zoledronic acid is due to come off patent soon, and should become less expensive.

Mortimer said more research is needed to evaluate which patients benefit from denosumab and zoledronic acid. Currently, "the available guidelines [from the American Society of Clinical Oncology] say to use one or the other," she said.

More information

To learn more about cancer's spread, visit the

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Newer Second-Line Diabetes Drug May Outperform Older Meds
3. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
4. Newer technology to control blood sugar works better than conventional methods
5. Newer hip reconstruction technique provides good outcomes for athletes
6. A better tool to diagnose tuberculosis
7. Job injuries among youth prompt calls for better safety standards
8. Students focus on creating a better cervical collar
9. Out-of-hand tree nut consumption associated with better diet quality in children and adults
10. Kidney cancer patients do better when whole kidney is not removed, U-M study shows
11. Kidney Cancer Patients Fare Better With Tumor Removal Only
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
(Date:7/31/2014)... Parsippany, NJ (PRWEB) July 31, 2014 A ... millions of people survive cancer and resume normal lives. This ... American Cancer Society, will affect one in seven American men ... are, has a five-year survival rate of nearly 100% and ... serious illness but most men diagnosed with the disease do ...
(Date:7/31/2014)... USHIO America’s Solid State Lighting ... lighting marketplaces, today announced the launch of its ... users to transform existing, inefficient lamp-based downlights to ... USHIO America’s Uphoria LED downlight retrofit kits fit ... the user to upgrade old incandescent recessed lighting ...
(Date:7/31/2014)... 2014 When guests shop CVS, they’ll find ... to Shea Moisture. And now CVS is adding another acclaimed ... August 1, guests will find G Natural products in CVS ... investment, CEO Roger Gore was inspired to start G’Natural Herbal ... and developing a receding hairline; he tried many products on ...
(Date:7/30/2014)... Calling all runners in the Richmond, VA region. , Tidewater ... monthly Runner’s Injury Clinic at the Glen Allen ... Monday of each month through the end of the year ... December 8. , The clinics run from 5:30 to ... and attire, will receive a complimentary evaluation of running injuries ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 WalkingSticksandCane.com ... Walking Canes. The ladies will love the new European fashions ... Sticks . These sticks and canes are from one from ... England. Each of the styles re unique and offer the ... , The Blackthorn Walking Sticks are some of the rarest ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 3Health News:European Walking Sticks from WalkingSticksandCane.com 2
... may be sharply divided in their views on many aspects ... in strong agreement when it comes to one of the ... According to results of the American College of Surgeons (ACS) ... support the establishment of a nationwide trauma system - including ...
... Most pregnant women consuming a typical,western diet obtain too ... which is critical for fetal and infant brain,development. This ... panel of nutrition experts summarized in the September 2007,Fats ... called,for pregnant and lactating women to consume at least ...
... a Top ... Priority at Newton-Wellesley, RESTON, Va. and ... announced Newton-Wellesley,s use of,the Isabel decision support system to aid ... the implementation,kicks off an initiative to affirm the quality of ...
... MESA, Ariz., Oct. 3 The Well Life Center ... and healthcare,education, announces the launch of its "10 Healing ... Donations benefit The Arizona,Special Olympics. This session will ... using the 10 universal laws. Discover how to set ...
... Prism Pharmaceuticals,Inc., a privately-held, specialty pharmaceutical company committed ... the appointment of Maurits W. Geerlings, MD, MBA, ... "I am pleased to welcome Dr. Geerlings to ... brings a tremendous amount of relevant,industry experience and ...
... Recently, a man, traveling on,business to Scranton, ... by,ambulance to Moses Taylor Hospital where clinicians identified ... recent seizure, the patient was unable to,communicate his ... registration, a form automatically printed out in the ...
Cached Medicine News:Health News:A nation divided over health care? Not so fast 2Health News:Brain, Eye and Heart Health: Three Reasons to Eat More Omega-3s 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 3Health News:Moses Taylor Hospital Automates Medication Reconciliation 2
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... WASHINGTON, Nov. 1 Multiple myeloma is one,of the ... U.S., but,survival rates have risen dramatically over the past ... to new types of drugs,and aggressive therapeutic interventions such ... studies prepublished online in Blood, the,official journal of the ...
... IRVINE, Calif., Nov. 1 IDM Pharma, Inc.,(Nasdaq: ... data,from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). ... funded cooperative,group study conducted by the Children,s Oncology Group ... of patients originally treated in the Phase,3 trial. The ...
Cached Medicine Technology:Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 2Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 3Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 2IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 3IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 5IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 6
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
Wright-Giemsa Stain Solutions...
Medicine Products: